Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simufilam safety study in mild-to-moderate Alzheimer's disease
NCT04388254Phase 2Completed
- Sponsor
- Cassava Sciences
- Start
- Mar 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of simufilam in Alzheimer's disease (AD), sponsored by Cassava Sciences. Started Mar 2020; status: completed.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04388254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388254.